March 16, 2016

Replacement Beats Repair for Severe Ischemic Mitral Regurgitation

CTSN findings are changing practice across the U.S.

Mitral Valve Repair

While mitral valve repair remains the gold standard for treating degenerative mitral valve disease, the preferred treatment of severe ischemic mitral valve regurgitation has now changed.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Two-year results from a randomized trial comparing mitral valve replacement with repair have led investigators to conclude that replacement should be the treatment of choice for severe ischemic mitral regurgitation. The multicenter study was published in the New England Journal of Medicine early this year by the NIH-funded Cardiothoracic Surgical Trials Network (CTSN), of which Cleveland Clinic is a member.

“We were surprised by the results,” says Cleveland Clinic cardiothoracic surgeon A. Marc Gillinov, MD, who was among the study’s lead authors. “This is already changing practice across the country.”

Not the same as degenerative mitral valve disease

Severe ischemic mitral valve regurgitation has a different etiology from degenerative mitral valve disease. The condition is caused by a heart attack that remodels the left ventricle, which distorts the valve and causes it to leak. The goal of surgery is to stop valve leakage.

Advertisement

“Patients are coming in for surgery for a combination coronary artery bypass graft and leaky mitral valve,” explains Dr. Gillinov.

Huge disparity in leakage rates

The CTSN study randomized 251 patients with severe ischemic mitral regurgitation to mitral valve repair or replacement and monitored their clinical and echocardiographic outcomes for two years. There were no significant between-group differences in survival or left ventricular reverse remodeling, but while mitral valve replacement stopped leakage for at least two years in all but 4 percent of patients, 59 percent of patients undergoing mitral valve repair had recurrent leakage within two years (P < .001).

The study authors write that the “deficiency in the durability of correction of mitral regurgitation is disconcerting” since recurrence predisposes patients to heart failure, atrial fibrillation, and repeat interventions and hospitalizations.

Advertisement

“There’s no way to predict which patients will have a repair that lasts,” Dr. Gillinov notes, “so replacement should be the first consideration.”

For more of Dr. Gillinov’s perspectives on this study, check out the short video here.

Related Articles

x-ray of bone fracture in a forearm
March 1, 2024
TRAVERSE Substudy Links Testosterone Therapy to Increased Fracture Risk in Older Men With Hypogonadism

Surprise findings argue for caution about testosterone use in men at risk for fracture

photo of intubated elderly woman in hospital bed
February 23, 2024
Proteomic Study Characterizes Markers of Frailty in Cardiovascular Disease and Their Links to Outcomes

Findings support emphasis on markers of frailty related to, but not dependent on, age

GettyImages-1252287413 [Converted]
September 8, 2023
Black Residents of Historically Redlined Areas Have Increased Heart Failure Risk

Large database study reveals lingering health consequences of decades-old discrimination

23-HVI-4172009 CQD 650&#215;450-2
August 29, 2023
Updates From CLEAR Outcomes and VALOR-HCM: Expanded Benefits With Bempedoic Acid and Mavacamten

Additional analyses of the two trials presented at 2023 ESC Congress

21-HVI-2577809_septal-myectomy-LVOTO-repair_650x450
January 6, 2022
Study Confirms Quality-of-Life Benefits of Myectomy in Obstructive HCM

Prospective SPIRIT-HCM trial demonstrates broad gains over 12-month follow-up

21-HVI-2211308 gender-scales_650x450
August 10, 2021
8 Ways to Increase Women’s Participation in Cardiovascular Trials

An ACC committee issues recommendations to accelerate sluggish progress

20-HVI-1998312_carotid-endarterectomy_650x450
December 4, 2020
Carotid Endarterectomy and the High-Risk Patient

Review of our recent experience shows it’s still a safe option

20-HVI-2006253-artificial-intelligence-heart-research_650x450
November 30, 2020
AI Looms Large in New Studies of Heart Transplant Rejection and Noncompaction Cardiomyopathy

Machine learning may improve risk prediction and guide therapy

Ad